CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis (NCT06223893) | Clinical Trial Compass
RecruitingNot Applicable
CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis
United Kingdom214 participantsStarted 2023-11-24
Plain-language summary
The CirrhoCare trial is a multi-centre, open label randomised controlled trial in patients with decompensated cirrhosis. The trial aims to investigate the clinical and cost-effectiveness of CirrhoCare digital home monitoring and management with current standard of care in these patients.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adults ≥ 18 years and diagnosed with cirrhosis of any aetiology.
✓. Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology. Cirrhosis of any aetiology may be included. However, participants with cirrhosis due to autoimmune hepatitis must be on a stable corticosteroid dose for ≥3-month period before study inclusion (to be recorded on concomitant log).
✓. Cirrhosis severity-risk defined by European-Foundation Consortium Liver Failure - Acute Decompensation score (CLIF-C AD score) ≥42 points but ≤65 points at the time of screening.
✓. Hospitalisation for acute decompensation \[determined as one or more of the following: increasing ascites, variceal haemorrhage, overt hepatic encephalopathy, spontaneous bacterial peritonitis (SBP) or hepatorenal syndrome - acute kidney injury (HRS-AKI)\].
✓. Participants able to give informed consent.
Exclusion criteria
✕. Participants with ACLF grade 2 and above according to the criteria published by Moreau
✕. Participants with CLIF-C AD score ≥ 66, who have a high mortality similar to ACLF ≥2 participants.
✕. Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the West-Haven classification, unable to give consent.
✕. Participants with active hepatocellular carcinoma (HCC) or history of HCC that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria.
What they're measuring
1
Number of hospital interventions from new-liver related complications
. Participants with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD \>2, chronic kidney disease with serum creatinine \>2mg/dL or under renal replacement therapy.
✕. Participants with documented refractory ascites on a palliative pathway.
✕. Participants who are active on the transplant waiting list.
✕. Participants with current extra hepatic malignancies including solid tumours and hematologic disorders.